Financial Performance - In Q4 2025, net sales increased by 60.1% to EUR 695.3 million compared to EUR 434.4 million in Q4 2024 [1] - Operating profit for Q4 2025 was EUR 328.1 million, more than tripling from EUR 92.7 million in Q4 2024 [2] - For the full year 2025, net sales reached EUR 1,889.5 million, a 22.5% increase from EUR 1,542.4 million in 2024 [1] - Full year operating profit was EUR 631.6 million, up 51.6% from EUR 416.6 million in 2024 [1] - Basic earnings per share for 2025 were EUR 3.56, a 51.5% increase from EUR 2.35 in 2024 [1] Business Divisions - The Innovative Medicines division saw net sales more than double in Q4 2025, driven by a EUR 180 million milestone and strong Nubeqa® sales [3] - The Branded Products and Generics and Consumer Health divisions also maintained solid growth, supported by high-quality portfolios [4] - The Animal Health division continued to perform well, contributing to overall sales stability [4] Research and Development - Orion initiated a phase 2 trial of ODM-212, a TEAD inhibitor, focusing on rare cancers, with plans to expand the program in 2026 [5] - A second phase 3 trial with levosimendan for pulmonary hypertension was also initiated by partner Tenax [5] Future Outlook - For 2026, net sales are estimated to be between EUR 1,900 million and EUR 2,100 million, with operating profit expected to range from EUR 550 million to EUR 750 million [12] - The growth in 2026 is anticipated to be driven by increasing Nubeqa® royalties and product sales [16] - The Branded Products division is expected to grow, particularly in the Respiratory therapy area and the Easyhaler® product portfolio [17] Dividend Proposal - The Board of Directors proposed a dividend of EUR 1.80 per share for 2025, to be paid in two instalments [7][8] - The first instalment of EUR 0.90 is proposed to be paid on April 2, 2026, and the second instalment on October 27, 2026 [8]

Core Insights - The company reported a decline in net sales and operating profit for Q3 2025, primarily due to the absence of major milestone payments that were recorded in the previous year [3][4][6] - Despite the reported decline, underlying net sales and operating profit showed significant growth when excluding major milestone payments [3][4] - The company has specified its outlook for 2025, projecting net sales between EUR 1,640 million and EUR 1,720 million, and operating profit between EUR 410 million and EUR 490 million [6][8] Financial Performance - Q3 2025 net sales were EUR 423.2 million, down 10.2% from EUR 471.3 million in Q3 2024 [2] - Q3 2025 operating profit was EUR 121.0 million, a decrease of 40.1% from EUR 202.0 million in Q3 2024 [2] - Basic earnings per share for Q3 2025 were EUR 0.68, down 40.4% from EUR 1.14 in Q3 2024 [2] - Research and development expenses increased by 35.8% in Q3 2025, totaling EUR 49.8 million [2] Business Segments - The Innovative Medicines division experienced a decline in reported net sales due to the absence of major milestone payments, although Nubeqa showed strong growth [4] - The Generics and Consumer Health divisions continued to grow solidly, while growth in Branded Products and Animal Health was more moderate [4] - The company anticipates growth in the Branded Products division driven by the Easyhaler product portfolio and other products [14] Market and Regulatory Developments - The European Commission approved darolutamide for use in patients with metastatic hormone-sensitive prostate cancer, which is expected to support Nubeqa's growth [5] - The company does not foresee a material impact from U.S. tariffs on its operations for the current year [5] Research and Development Focus - The company has discontinued the development of ODM-105 for insomnia due to lack of efficacy in clinical trials and will focus on advancing other assets [7] - Orion aims to initiate a Phase 2 program with ODM-212 in oncology next year and plans to bring at least one biological candidate to clinical development [7][8] Capital Expenditure and Financial Outlook - Capital expenditure is expected to grow in 2025, reflecting the company's commitment to strengthening its research and development pipeline [18] - The outlook for 2025 has been revised to reflect anticipated growth in net sales and operating profit, excluding any material milestone payments [6][11]

Core Insights - Orion Corporation reported significant growth in net sales and operating profit for the first half of 2025, with net sales increasing by 21.1% to EUR 771.0 million and operating profit rising by 49.8% to EUR 182.5 million [1][4][8] - The company upgraded its outlook for 2025, estimating net sales between EUR 1,630 million and EUR 1,730 million, and operating profit between EUR 400 million and EUR 500 million [4][8] Financial Performance - In Q2 2025, net sales reached EUR 416.5 million, a 26.9% increase from EUR 328.2 million in Q2 2024 [1][4] - EBITDA for Q2 2025 was EUR 118.6 million, up 50.6% from EUR 78.8 million in Q2 2024, representing 28.5% of net sales [1][4] - Basic earnings per share for Q2 2025 were EUR 0.59, compared to EUR 0.37 in Q2 2024, marking a 58.7% increase [1][4] Business Segments - The performance of Nubeqa® was highlighted as a key driver of growth, with both royalty income and product sales showing strong increases [3][4] - The Branded Products and Animal Health divisions also reported double-digit growth, contributing to the overall positive performance [4][5] Research and Development - Research and development expenses increased by 12.5% to EUR 49.1 million in Q2 2025, reflecting the company's commitment to innovation [1][4] - The company opened a new research and development center in Cambridge, UK, and expanded collaborations in various business areas [6][7] Market Outlook - The outlook for 2025 anticipates continued growth in Nubeqa® royalties and product sales, although predicting exact levels remains challenging [12][14] - The Branded Products division is expected to grow, driven by the Easyhaler® product portfolio and other products, while the Animal Health division is anticipated to see slight growth [13]

Core Insights - Orion is hosting its Capital Markets Day on May 22, 2025, in Helsinki, focusing on its growth strategy and financial objectives without announcing new targets [1][5] - The company has three biologics assets in late research phases for immuno-oncology, with plans to initiate clinical phase I trials within the next 12 to 24 months [3][7] - Orion's Easyhaler® product portfolio for asthma and COPD is expected to exceed EUR 300 million in peak annual sales, driven by a shift towards dry-powder inhalers due to lower CO2 emissions [4][7] Company Overview - Orion is a Nordic pharmaceutical company with over a hundred years of experience, developing and marketing human and veterinary pharmaceuticals [6] - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [6]